Gyre Therapeutics, Inc.

The end of 2023 is proving no different from the end of any other year, with venture capital firms and biopharmaceutical companies closing out a flurry of new VC funds and financings before December d

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. AnnJi Licenses Muscular Atrophy Ca

CSL Limited / uniQure N.V. ’s hemophilia B gene therapy, Hemgenix, has been given a thumbs up from the European Commission but historical and recent mishaps faced by other gene therapies on the Europe

Pfizer Inc. is set to challenge uniQure N.V. / CSL Limited ’s Hemgenix after the former’s adeno-associated virus (AAV)-based gene therapy asset for hemophilia B passed a Phase III trial, sparking pl